Novel Therapies for Thyroid Autoimmune Diseases

Expert Review of Clinical Pharmacology

Volumn 9, Issue 6, 2016, Pages 853-861

  Fallahi, Poupak ^a   Ferrari, Silvia Martina ^a   Elia, Giusy ^a   Nasini, Francesco ^a   Colaci, Michele ^b   Giuggioli, Dilia ^b   Vita, Roberto ^c   Benvenga, Salvatore ^c   Ferri, Clodoveo ^b   Antonelli, Alessandro ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

Autoimmune thyroiditis; chemokines; corticosteroids; CXCL10; CXCR3; Graves disease; Graves Ophthalmopathy; rituximab; teprotumumab; tocilizumab

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CIPROFIBRATE; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; ELDELUMAB; ETANERCEPT; FENOFIBRATE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GEMFIBROZIL; HORMONE RECEPTOR BLOCKING AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RITUXIMAB; ROSIGLITAZONE; SOMATOMEDIN C RECEPTOR; TEPROTUMUMAB; THYROTROPIN RECEPTOR; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; CHEMOKINE; CXCR3 PROTEIN, HUMAN;

AUTOIMMUNE THYROIDITIS; CORTICOSTEROID THERAPY; CYTOKINE RELEASE; DRUG TARGETING; ENDOCRINE OPHTHALMOPATHY; GENE EXPRESSION; HASHIMOTO DISEASE; HUMAN; INTERFERON PRODUCTION; NONHUMAN; PATHOGENESIS; REVIEW; TH1 CELL; TRANSCRIPTION INITIATION; ANIMAL; DRUG DESIGN; DRUG EFFECTS; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; METABOLISM; PATHOPHYSIOLOGY; THYROIDITIS, AUTOIMMUNE;

ANIMALS; CHEMOKINES; DRUG DESIGN; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; HUMANS; INTERFERON-GAMMA; RECEPTORS, CXCR3; THYROIDITIS, AUTOIMMUNE;

EID: 84961203755     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2016.1157468     Document Type: Review

References (92)

1. B.Vaidya, S.H.Pearce Diagnosis and management of thyrotoxicosis. BMJ. 2014;349:g5128.
2. I.B.Pedersen, P.Laurberg, N.Knudsen, et al. An increased incidence of overthypothyroidism after iodine fortification of salt in Denmark: a prospective population study. J Clin Endocrinol Metab. 2007;92:3122–3127.
3. M.Rizzo, R.T.Rossi, O.Bonaffini, et al. Increased annual frequency of Hashimoto’s thyroiditis between years 1988 and 2007 at a cytological unit of Sicily. Ann Endocrinol (Paris). 2010;71:525–534.
4. A.Antonelli, S.M.Ferrari, A.Corrado, et al. Autoimmune thyroid disorders. Autoimmun Rev. 2015;14:174–180.•• A comprehensive review about autoimmune thyroid disorders.
5. J.Ma, D.Wu, C.Li, et al. Lower serum 25-hydroxyvitamin D level is associated with 3 types of autoimmune thyroid diseases. Medicine (Baltimore). 2015;94:e1639.
6. S.Tognini, G.Pasqualetti, V.Calsolaro, et al. Cognitive function and quality of life in mild thyroid hormone deficiency. Recent Pat Endocr Metab Immune Drug Discov. 2014;8:124–134.
7. W.M.Wiersinga. Quality of life in Graves’ ophthalmopathy. Best Pract Res Clin Endocrinol Metab. 2012;26:359–370.
8. R.S.Bahn. Graves’ ophthalmopathy. N Engl J Med. 2010;362:726–738.
9. T.J.Smith. Pathogenesis of Graves’ orbitopathy: a 2010 update. J Endocrinol Invest. 2010;33:414–421.
10. W.B.Minich, N.Dehina, T.Welsink, et al. Autoantibodies to the IGF1 receptor in Graves’ orbitopathy. J Clin Endocrinol Metab. 2013;98:752–760.
11. J.R.Wall, H.Lahooti, I.El Kochairi, et al. Thyroid-stimulating immunoglobulins as measured in a reporter bioassay are not detected in patients with Hashimoto’s thyroiditis and ophthalmopathy or isolated upper eyelid retraction. Clin Ophthalmol. 2014;8:2071–2076.
12. H.Lahooti, K.R.Parmar, J.R.Wall. Pathogenesis of thyroid-associated ophthalmopathy: does autoimmunity against calsequestrin and collagen XIII play a role? Clin Ophthalmol. 2010;4:417–425.
13. T.H.Brix, L.Hegedüs. Twin studies as a model for exploring the aetiology of autoimmune thyroid disease. Clin Endocrinol (Oxf). 2012;76:457–464.•• A comprehensive review about twin studies in autoimmune thyroid disorders.
14. P.Laurberg, T.Jørgensen, H.Perrild, et al. The Danish investigation on iodine intake and thyroid disease, DanThyr: status and perspectives. Eur J Endocrinol. 2006;155:219–228.
15. A.Carlé, I.Bülow Pedersen, N.Knudsen, et al. Smoking cessation is followed by a sharp but transient rise in the incidence of overt autoimmune hypothyroidism - a population-based case-control study. Clin Endocrinol (Oxf). 2012;77:764–772.
16. A.Drutel, F.Archambeaud, P.Caron. Selenium and the thyroid gland: more good news for clinicians. Clin Endocrinol (Oxf). 2013;78:155–164.
17. R.Desailloud, D.Hober. Viruses and thyroiditis: an update. Virol J. 2009;6:5.
18. T.P.Giordano, L.Henderson, O.Landgren, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007;297:2010–2017.
19. G.Indolfi, S.Stagi, E.Bartolini, et al. Thyroid function and anti- thyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection. Clin Endocrinol (Oxf). 2008;68:117–121.
20. A.Antonelli, C.Ferri, P.Fallahi, et al. Thyroid disorders in chronic hepatitis C virus infection. Thyroid. 2006;16:563–572.
21. A.Antonelli, C.Ferri, P.Fallahi, et al. Alpha-chemokine CXCL10 and beta-chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis. Metabolism. 2008;57:1270–1277.
22. A.Antonelli, C.Ferri, P.Fallahi, et al. High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis. Cytokine. 2008;42:137–143.
23. J.T.Blackard, L.Kong, A.K.Huber, et al. Hepatitis C virus infection of a thyroid cell line: implications for pathogenesis of hepatitis C virus and thyroiditis. Thyroid. 2013;23:863–870.
24. F.Menconi, A.Hasham, Y.Tomer. Environmental triggers of thyroiditis: hepatitis C and interferon-α. J Endocrinol Invest. 2011;34:78–84.
25. M.J.Simmonds. GWAS in autoimmune thyroid disease: redefining our understanding of pathogenesis. Nat Rev Endocrinol. 2013;9:277–287.•• A comprehensive review about GWAS in autoimmune thyroid disease.
26. M.Rotondi, F.Coperchini, F.Magri, et al. Serum-negative autoimmune thyroiditis: what’s in a name? J Endocrinol Invest. 2014;37:589–591.
27. H.Lahooti, D.Cultrone, S.Edirimanne, et al. Novel single-nucleotide polymorphisms in the calsequestrin-1 gene are associated with Graves’ ophthalmopathy and Hashimoto’s thyroiditis. Clin Ophthalmol. 2015;9:1731–1740.
28. M.Rotondi, A.Falorni, A.De Bellis, et al. Elevated serum interferon-gamma-inducible chemokine-10/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines. J Clin Endocrinol Metab. 2005;90:2357–2363.
29. M.Dittmar, G.J.Kahaly. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J Clin Endocrinol Metab. 2003;88:2983–2992.
30. A.Antonelli, P.Fazzi, P.Fallahi, et al. Prevalence of hypothyroidism and Graves disease in sarcoidosis. Chest. 2006;130:526–532.
31. A.Antonelli, P.Fallahi, M.Mosca, et al. Prevalence of thyroid dysfunctions in systemic lupus erythematosus. Metabolism. 2010;59:896–900.
32. A.Antonelli, C.Ferri, P.Fallahi, et al. Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis. Eur J Endocrinol. 2007;156:431–437.
33. N.Alfaris, R.Curiel, S.Tabbara, et al. Autoimmune thyroid disease and Sjögren syndrome. J Clin Rheumatol. 2010;16:146–147.
34. B.Namjou, J.A.Kelly, J.Kilpatrick, et al. Linkage at 5q14.3-15 in multiplex systemic lupus erythematosus pedigrees stratified by autoimmune thyroid disease. Arthritis Rheum. 2005;52:3646–3650.
35. A.Antonelli, C.Ferri, P.Fallahi, et al. Thyroid cancer in HCV-related mixed cryoglobulinemia patients. Clin Exp Rheumatol. 2002;20:693–696.
36. E.Fiore, T.Rago, F.Latrofa, et al. Hashimoto’s thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer. 2011;18:429–437.
37. F.Boi, L.Minerba, M.L.Lai, et al. Both thyroid autoimmunity and increased serum TSH are independent risk factors for malignancy in patients with thyroid nodules. J Endocrinol Invest. 2013;36:313–320.
38. A.Antonelli, S.M.Ferrari, D.Giuggioli, et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev. 2014;13:272–280.•• A comprehensive review about Th1 chemokines in autoimmune thyroid disorders.
39. A.Antonelli, P.Fallahi, S.M.Ferrari, et al. Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study. Diabet Med. 2008;25:1349–1353.
40. A.Antonelli, S.M.Ferrari, P.Fallahi, et al. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists. Endocr Relat Cancer. 2009;16:1299–1311.
41. A.Antonelli, S.M.Ferrari, S.Frascerra, et al. Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10. Cytokine. 2011;55:288–293.
42. M.Rotondi, L.Chiovato, S.Romagnani, et al. Role of chemokines in endocrine autoimmune diseases. Endocr Rev. 2007;28:492–520.
43. M.Rotondi, L.Chiovato. The chemokine system as a therapeutic target in autoimmune thyroid diseases: a focus on the interferon-γ inducible chemokines and their receptor. Curr Pharm Des. 2011;17:3202–3216.
44. H.Kimura, M.Kimura, N.R.Rose, et al. Early chemokine expression induced by interferon-gamma in a murine model of Hashimoto’s thyroiditis. Exp Mol Pathol. 2004;77:161–167.
45. A.Antonelli, M.Rotondi, S.M.Ferrari, et al. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves’ ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab. 2006;91:614–620.
46. J.R.Groom, A.D.Luster. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol. 2011;89:207–215.
47. A.Antonelli, S.M.Ferrari, P.Fallahi, et al. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves’ disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab. 2009;94:1803–1809.
48. S.D.Lytton, G.J.Kahaly. Bioassays for TSH-receptor autoantibodies: an update. Autoimmun Rev. 2010;10:116–122.
49. P.Romagnani, M.Rotondi, E.Lazzeri, et al. Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves’ disease. Am J Pathol. 2002;161:195–206.
50. A.Antonelli, M.Rotondi, P.Fallahi, et al. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves’ disease, and modulation by methimazole therapy. Clin Endocrinol (Oxf). 2006;64:189–195.
51. Y.Inukai, A.Momobayashi, N.Sugawara, et al. Changes in expression of T-helper (Th) 1- and Th2-associated chemokine receptors on peripheral blood lymphocytes and plasma concentrations of their ligands, interferon-inducible protein-10 and thymus and activation-regulated chemokine, after antithyroid drug administration in hyperthyroid patients with Graves’ disease. Eur J Endocrinol. 2007;156:623–630.
52. P.Brück, W.Bartsch, D.Sadet, et al. A CXC motif ligand 10 polymorphism as a marker to predict severity of Graves’ disease. Thyroid. 2010;20:343–345.
53. H.Sakai, Y.Togawa, G.Fukuda, et al. Serum chemokine (C-X-C motif) ligand 10 levels are elevated in patients with Graves’ disease in long-term remission. Thyroid. 2010;20:341–342.
54. A.Antonelli, P.Fallahi, M.Rotondi, et al. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves’ disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg. 2006;93:1226–1231.
55. A.Antonelli, M.Rotondi, P.Fallahi, et al. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves’ disease or toxic nodular goiter. J Clin Endocrinol Metab. 2007;92:1485–1490.
56. A.C.Leite, A.B.Pedro, J.H.Romaldini. Influence of methimazole and radioactive iodine treatment in the serum levels of the chemokine CXCL10 in hyperthyroid patients with Graves’ disease. Horm Metab Res. 2011;43:194–199.
57. E.Fuentes, L.Guzmán-Jofre, R.Moore-Carrasco, et al. Role of PPARs in inflammatory processes associated with metabolic syndrome (Review). Mol Med Rep. 2013;8:1611–1616.
58. K.L.Schaefer, S.Denevich, C.Ma, et al. Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm Bowel Dis. 2005;11:244–252.
59. J.W.Lee, P.J.Bajwa, M.J.Carson, et al. Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10 deficient mice. Gastroenterology. 2007;133:108–123.
60. A.Antonelli, S.M.Ferrari, S.Frascerra, et al. Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves’ disease. Exp Cell Res. 2011;317:1527–1533.
61. A.Antonelli, S.M.Ferrari, S.Frascerra, et al. CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves’ and normal thyrocytes. J Clin Endocrinol Metab. 2010;95:E413–E420.
62. P.Delerive, K.De Bosscher, S.Besnard, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem. 1999;274:32048–32054.
63. C.Crescioli, L.Cosmi, E.Borgogni, et al. Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. J Endocrinol. 2007;195:145–155.
64. M.Yellin, I.Paliienko, A.Balanescu, et al. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2012;64:1730–1739.•• A very interesting study about MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in patients with rheumatoid arthritis.
65. L.Mayer, W.J.Sandborn, Y.Stepanov, et al. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014;63:442–450.
66. L.Bartalena, G.E.Krassas, W.Wiersinga, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97:4454–4463.
67. A.Ahuja, S.M.Anderson, A.Khalil, et al. Maintenance of the plasma cell pool is independent of memory B cells. Proc Natl Acad Sci U S A. 2008;105:4802–4807.
68. J.C.Edwards, L.Szczepanski, J.Szechinski, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572–2581.
69. J.Descotes. Immunotoxicity of monoclonal antibodies. MAbs. 2009;1:104–111.
70. Food and Drug Administration. FDA Public Health Advisory: life-threa-tening brain infection in patients with systemic lupus erythematosus after Rituxan (rituximab) treatment. 2006. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124345.htm
71. E.S.Molloy, L.H.Calabrese. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev. 2008;8:144–146.
72. M.Salvi, G.Vannucchi, N.Curro`, et al. A small dose of rituximab for graves orbitopathy: new insights into the mechanism of action. Arch Ophthalmol. 2012;130:122–124.
73. A.L.Mitchell, E.H.Gan, M.Morris, et al. The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves’ orbitopathy. Clin Endocrinol (Oxf). 2013;79:437–442.• An interesting study about rituximab in Graves’ orbitopathy.
74. M.N.Stan, J.A.Garrity, B.G.Carranza Leon, et al. Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab. 2015;100:432–441.•• A very interesting study about rituximab in Graves’ orbitopathy.
75. M.Salvi, G.Vannucchi, N.Currò, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100:422–431.•• A very interesting study about rituximab in Graves’ orbitopathy.
76. C.H.Emerson. When will thyrotropin receptor antagonists and inverse thyrotropin receptor agonists become available for clinical use? Thyroid. 2011;21:817–819.
77. A.F.Turcu, S.Kumar, S.Neumann, et al. A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy. J Clin Endocrinol Metab. 2013;98:2153–2159.•• A very interesting study about a small molecule antagonist that inhibits thyrotropin receptor in Graves’ orbitopathy.
78. M.Salvi. Immunotherapy for Graves’ ophthalmopathy. Curr Opin Endocrinol Diabetes Obes. 2014;21:409–414.
79. T.J.Smith. Is IGF-I receptor a target for autoantibody generation in Graves’disease? J Clin Endocrinol Metab. 2013;98:515–518.•• A comprehensive review about IGF-I receptor as target for autoantibody generation in Graves’disease.
80. H.Chen, T.Mester, N.Raychaudhuri, et al. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab. 2014;99:E1635–E1640.
81. H.Chen, S.J.Shan, T.Mester, et al. TSH-mediated TNFα production in human fibrocytes is inhibited by teprotumumab, an IGF-1R antagonist. PLoS One. 2015;10:e0130322.
82. L.J.Scott. Etanercept: a review of its use in autoimmune inflammatory diseases. Drugs. 2014;74:1379–1410.•• A comprehensive review of etanercept and its use in autoimmune inflammatory diseases.
83. D.Paridaens, W.A.van den Bosch, T.L.van der Loos, et al. The effect of etanercept on Graves’ ophthalmopathy: a pilot study. Eye (Lond). 2005;19:1286–1289.
84. M.Salvi, G.Girasole, M.Pedrazzoni, et al. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves’ disease. J Clin Endocrinol Metab. 1996;81:2976–2979.
85. P.Emery, E.Keystone, H.P.Tony, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67:1516–1523.
86. S.Yokota, T.Imagawa, M.Mori, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006.
87. J.V.Pérez-Moreiras, A.Alvarez-López, E.C.Gómez. Treatment of active corticosteroid-resistant graves’ orbitopathy. Ophthal Plast Reconstr Surg. 2014;30:162–167.• An interesting study about tocilizumab in Graves’ orbitopathy.
88. J.P.Aniszewski, R.W.Valyasevi, R.S.Bahn. Relationship between disease duration and predominant orbital T cell subset in Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2000;85:776–780.
89. Y.Hiromatsu, H.Fukazawa, J.R.Wall. Cytotoxic mechanisms in autoimmune thyroid disorders and thyroid-associated ophthalmopathy. Endocrinol Metab Clin North Am. 1987;16:269–286.
90. J.Mysliwiec, I.Palyga, M.Kosciuszko, et al. Circulating CXCL9 and CXCL10 as markers of activity of Graves’ orbitopathy during treatment with corticosteroids and teleradiotherapy. Horm Metab Res. 2012;44:957–961.
91. W.Zhu, L.Ye, L.Shen, et al. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2014;99:1999–2007.
92. A.Antonelli, S.M.Ferrari, P.Fallahi, et al. Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. Metabolism. 2011;60:277–283.